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Although the incidence of gastric cancer has been declining in the
Western world, it is the most common malignancy in many other
countries including Korea (Kim et al, 1989; Fuchs and Mayer,
1995). Curative surgery is an essential treatment for the long-term
survival of patients with gastric cancer (Noguchi et al, 1989; Shiu
et al, 1989; Fuchs and Mayer, 1995). However, the prognosis of
patients with locally advanced gastric cancer is generally poor
even with curative resection (Noguchi et al, 1989; Shiu et al, 1989;
Fuchs and Mayer, 1995). Adjuvant chemotherapy has failed to
demonstrate a significant survival benefit for such patients in most
randomized trials and meta-analyses, except in a few studies with
positive results (Shiu et al, 1989; Krook et al, 1991; Kim et al,
1992; Hermans et al, 1993; Nakazato et al, 1994; Fuchs and Mayer,
1995; Lise et al, 1995; Macdonald et al, 1995; Kelsen, 1996; Kim et
al, 1998; Cirera et al, 1999; Earle and Maroun, 1999). 
In adjuvant chemotherapy of gastric cancer, 5-fluorouracil (5-FU)
has been considered as one of the standard chemotherapeutic agents
and is usually combined with other agents such as doxorubicin and
mitomycin-C (Krook et al, 1991; Kim et al, 1992; Nakazato et al,
1994; Lise et al, 1995; Macdonald et al, 1995; Kelsen, 1996; Kim et
al, 1998). Thymidylate synthase (TS) catalyzes the methylation of
deoxyuridine monophosphate to deoxythymidine monophosphate,
which is an essential process for DNA synthesis (Pinedo and Peters,
1988). TS is also a critical target of 5-FU. In tumour cells, 5-FU is
converted to 5-fluorodeoxyuridine monophosphate, which forms a
tight-binding covalent complex with TS in the presence of folate
cofactor 5, 10-methylene tetrahydrofolate (Pinedo and Peters, 1988).
Several preclincal and clinical studies have demonstrated that
increased expression of TS may be associated with 5-FU resistance in
a variety of malignancies (Washtien, 1984; Johnston et al, 1992;
Johnston et al., 1995; Lenz et al, 1996; Boku et al, 1998; Yeh, et al,
1998). 
In gastric cancer, several studies have shown that TS expression has
an inverse relationship with response to chemotherapy and survival in
patients with locally advanced or metastatic disease receiving
systemic chemotherapy with 5-FU-containing regimens (Johnston et
al, 1995; Lenz et al, 1996; Boku et al, 1998; Yeh, et al, 1998).
Moreover, TS expression also predicted poor disease-free and overall
survival in a few reports that investigated gastric cancer patients
treated with 5-FU-based adjuvant chemotherapy after surgical resec-
tion (Kuniyasu et al, 1998; Suda et al, 1999). We evaluated the expres-
sion of TS using immunohistochemistry in primary tumours of locally
advanced gastric cancer patients treated with 5-FU and doxorubicin-
based adjuvant chemotherapy after curative resection and investigated
the association between TS expression and various clinicopathologic
characteristics including prognosis of the patients. 
MATERIALS AND METHODS 
Patients 
Included in this study were 103 patients with locally advanced
gastric adenocarcinoma who underwent 5-FU and doxorubicin-
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doi: 10.1054/ bjoc.2000.1553, available online at http://www.idealibrary.com on  http://www.bjcancer.combased adjuvant chemotherapy after curative surgical resection at
Ajou University Medical Center in Suwon, Korea, between July
1994 and October 1996. All patients had a postsurgical pathologic
stage ranging from IB to IV without evidence of distant metastasis
according to the American Joint Committee on Cancer TNM clas-
sification (American Joint Committee on Cancer, 1997). Curative
resection was defined by the General Rules for the Gastric Cancer
Study in Surgery and Pathology of the Japanese Research Society
for Gastric Cancer as: no involvement of surgical stumps; suffi-
cient lymphatic dissection (R number ³ N number); no distant
metastasis; removal of involved adjacent organs and structures by
combined en-bloc resection; and no gross residual disease
(Japanese Research Society for Gastric Cancer, 1981). None of
these patients received chemotherapy prior to surgery. 
Although all patients received 5-FU and doxorubicin-based adju-
vant chemotherapy, the regimens were not uniform. The
most commonly administered regimen was FA (5-FU, doxorubicin)
with OK-432 (51 patients), followed by FAM (5-FU, doxorubicin,
mitomycin-C) (33 patients), FA (11 patients), and FA with lentinan
(eight patients). Chemotherapy was usually started 2–3 weeks after
surgery. In the FA regimen with or without immunotherapy (OK-432
or lentinan), 5-FU (500 mg m–2 day–1) was given by intravenous (iv)
infusion for 30 min on day 1, 8, 15, and doxorubicin (40 mg m–2) was
given by rapid iv injection on day 1. The treatment was repeated
every 3 weeks for 12 cycles. OK-432 (2.0 Klinishe Einheit day–1) and
lentinan (2 mg day–1) were administered intramuscularly and intra-
venously, respectively, weekly throughout the FA chemotherapy
period. In the FAM regimen, 5-FU (1000 mg m–2 day–1) was given by
continuous iv infusion on days 1–3, and doxorubicin (40 mg m–2) and
mitomycin-C (10 mg m–2, every other cycle) were administered by
rapid iv injection on day 1. The treatment was repeated every 4
weeks for 12 cycles and mitomycin-C was administered every 8
weeks. Patients were evaluated weekly during the treatment period
and every 3 months after completion of chemotherapy. Follow-up
studies were performed every 6 months: blood cell count and blood
chemistry, chest X-ray, abdominal ultrasonograpy or computed
tomography, and upper gastrointestinal series or esophagogastroduo-
denoscopy.
Immunohistochemical staining 
Formalin-fixed, paraffin-embedded tissue sections of 4 mM thick-
ness were deparaffinized in xylene and rehydrated through graded
alcohols. After microwave pretreatment in citrate buffer (pH 6.0) for
antigen retrieval, slides were immersed in 0.3% hydrogen peroxide
for 20 min to block the endogenous peroxidase activity. After
washing, slides were incubated overnight at 4˚C with the TS 106
mouse monoclonal antibody against TS (Neomarkers, Fremont, CA,
USA) at a dilution of 1:100. The slides were then stained by the
avidin–biotin-complex (ABC) peroxidase method with commer-
cially available UltraTech HRP kit (Immunotech, Marseilles,
France) according to the instructions of the manufacturer. Reaction
products were visualized by immersing slides in diaminobenzidine
tetrahydrochloride. Finally, the slides were counterstained with
Mayer’s haematoxylin and mounted with glass coverslips. 
Formalin-fixed, paraffin-embedded sections of colon adenocar-
cinoma known to have high expression of TS were used as positive
controls. The negative controls were made by the omission of the
primary antibody during the process of immunohistochemical
staining. 
Tissue evaluation 
The slides were examined independently by two observers (HJJ
and KBL) blinded to both clinical and pathologic data. TS expres-
sion was quantified using a visual grading system based on the
extent of staining, focal pattern (< 25% of tumour cells positive or
no staining) or diffuse pattern (³25% of tumour cells positive) as
well as the intensity of staining (0–3+) (Figure 1). There was close
agreement (> 90%) in the TS evaluation between both investiga-
tors. In case of disagreement, final grading was determined by
consensus. The expression of TS was divided into high-TS (diffuse
pattern) and low-TS (focal pattern) groups according to the extent
of staining. 
Statistical analysis 
Disease-free survival and overall survival were calculated using
the Kaplan–Meier method (Kaplan and Meier, 1958). Disease-free
survival was defined as the time from the day of operation to a
documented recurrence, or second primary cancer, or death from
any other cause. Data on patients who did not have a recurrence
were censored at the last follow-up. Overall survival was defined
as the time from the day of operation to death; data on survivors
were censored at the last follow-up. The differences between the
survival curves were tested by using the log-rank test. Comparison
of variables according to TS expression was evaluated with the
Student’s t-test and chi-square test. 
RESULTS 
Patient characteristics 
Of 103 patients who were assessable by TS staining, 71 were male
and 32 were female, and their median age was 53 years (range
28–72). Stages were IB in nine, II in 28, IIIA in 31, IIIB in 17, and
IV in 18 patients. The median number of chemotherapy cycles was
eight (range 1–13). 
Association of TS expression with patient and tumour
characteristics 
TS staining pattern in gastric tumours showed predominantly a
granular cytoplasmic staining in tumour cells (Figure 1). In some
tumor tissues, positive nuclear staining for TS was present in addi-
tion to cytoplasmic staining (Figure 1). Within the study group, 65
patients (63%) had primary tumours with high TS expression
(³ 25% of tumour cells positive), and 38 patients (37%) demon-
strated low TS expression (< 25% of tumour cells positive or no
staining). 78% of the tumours showed high intensity of staining
(intensity 2+ or 3+), whereas 22% had low intensity of staining
(intensity 0 or 1+). All tumours with diffuse pattern (³ 25% of
tumour cells positive) in the extent of staining demonstrated high
intensity of staining (intensity 2+ or 3+). 
The proportion of male was higher in high-TS group (80%)
compared with low-TS group (50%) (P = 0.002). In tumour differ-
entiation, poorly differentiated histology was more common in the
high-TS group (43%) than in the low-TS group (24%) (P = 0.015).
TS expression was also associated with Lauren’s classification
(P = 0.027). Mixed-type tumours were more frequently observed
in the high-TS group (40%) compared with the low-TS
group (21%). There was no significant association between TS
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age, type of operation, primary tumour size, location of tumour,
depth of tumour invasion, lymph node metastasis, postoperative
pathologic stage, and regimens of chemotherapy (Table 1). 
Association of TS expression with outcome of patients 
The median follow-up duration of the survivors was 51 months
(range 36–63) and no patient was lost to follow-up. At the time of
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Figure 1 Immunohistochemical staining of thymidylate synthase (TS) in gastric cancer. (A) Diffuse, high intensity (3+) TS staining in both cytoplasm and
nucleus of gastric cancer cells in contrast with no immunoreactivity in normal gastric mucosa (´ 100). (B) Diffuse, high intensity (3+) TS staining in well
differentiated tubular adenocarcinoma ( ´ 200). (C) Diffuse, high intensity (3+) TS staining in signet-ring cell carcinoma ( ´ 200). (D) Focal, high intensity (3+) TS
staining in well differentiated adenocarcinoma area in contrast with negative immunostaining in moderately to poorly differentiated adenocarcinoma area
( ´  100). (E) Focal, low intensity (1+) TS staining in moderately differentiated tubular adenocarcinoma ( ´ 200) 
A B
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Eanalysis, 38 patients had recurrences, and two had second primary
cancer (hepatocellular carcinoma and laryngeal cancer). 42 of the
103 patients have died. Death due to recurrence of gastric cancer
occurred in 37 patients. One patient died of gastrointestinal
bleeding without evidence of recurrence, one patient died of second
primary cancer (hepatocellular carcinoma), and the causes of death
were undetermined in three patients. There was no statistically
significant difference in 4-year disease-free survival between high-
TS group and low-TS group (60.0% vs 57.2%, P = 0.548) (Figure 2).
Four-year overall survival also demonstrated no significant differ-
ence between the two groups (59.6% vs 59.3%, P= 0.792) (Figure 3).
In the intensity of TS staining, no differences in disease-free
survival (P = 0.420) and overall survival of the patients (P = 0.769)
were noted between high-intensity group and low-intensity group.
There were no significant differences in disease-free survival and
overall survival according to other clinicopathologic characteristics
except primary tumour location (Table 2). 
DISCUSSION 
Both 5-FU and doxorubicin are effective agents in the chemo-
therapy of gastric cancer in the adjuvant setting, as well as in
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Table 1 Characteristics of patients according to TS expressiona
Characteristics Low TS High TS P value
Age (years) 50.6 ± 9.8 53.1 ± 9.3  0.195 
Gender 0.002 
Male 19 (50) 52 (80) 
Female 19 (50) 13 (20) 
Type of operation 0.410 
Subtotal 27 (71) 41 (63) 
Total 11 (29) 24 (37) 
Primary tumour size (cm) 6.2 ± 3.4 5.7 ± 2.4 0.332 
Tumour location 0.086 
Lower 21 (55) 34 (52) 
Mid 9 (24) 24 (37) 
Upper 5 (13) 7 (11) 
Diffuse 3 (8) 0 (0) 
Borrmann type 0.403 
I 1 (3) 5 (8) 
II 11 (29) 12 (19) 
III 21 (55) 42 (65) 
IV 5 (13) 6 (9) 
Tumour differentiation 0.015 
Well 3 (8) 10 (15) 
Moderate 12 (32) 19 (29) 
Poor 9 (24) 28 (43) 
Signet-ring 9 (24) 8 (12) 
Undifferentiated 1 (3) 0 (0) 
Mucinous 4 (10) 0 (0) 
Lauren’s classification 0.027 
Intestinal 22 (58) 35 (54) 
Diffuse 8 (21) 4 (6) 
Mixed 8 (21) 26 (40) 
Lymphatic invasion 0.915 
Yes 29 (76) 49 (75) 
No 9 (24) 16 (25) 
Depth of tumour invasion 0.368 
T2 17 (45) 25 (39) 
T3 21 (55) 37 (57) 
T4 0 (0) 3 (5) 
Lymph node involvement 0.698 
N0 7 (18) 11 (17) 
N1 15 (40) 26 (40) 
N2 12 (32) 16 (25) 
N3 4 (10) 12 (19) 
Stage 0.415 
IB 4 (10) 5 (8) 
II 9 (24) 19 (29) 
IIIA 15 (40) 16 (25) 
IIIB 6 (16) 11 (17) 
IV 4 (10) 14 (21) 
Chemotherapy 0.396 
FA + OK-432b 21 (55) 30 (46) 
FAMb 11 (29) 22 (34) 
FA 5 (13) 6 (9) 
FA + lentinan 1 (3) 7 (11) 
Cycles of chemotherapy 8.0 ± 4.0 8.8 ± 3.3 0.243 
aValues are number or mean ± standard deviation, with percentages in parentheses; bF, 5-FU, A, doxorubicin, M, mitomycin-C.unresectable or metastatic disease (Kim et al, 1992; Nakazato et al,
1994; Kelsen, 1996; Wils, 1996; Kim et al, 1998). Biological
markers, which can predict the resistance of tumours to these
agents, may provide valuable information in the treatment of
gastric cancer with systemic chemotherapy. In this study, we eval-
uated the clinical significance of TS expression as a prognostic
marker of recurrence and survival in locally advanced gastric
cancer patients treated with 5-FU and doxorubicin-based adjuvant
chemotherapy after curative resection. 
In terms of TS expression in primary tumours, 63% of tumours
demonstrated high expression of TS. The proportion of the
patients with high TS expression in the current study seems to be
high compared to other reports that evaluated the TS expression
with surgically resected gastric cancer tissues by immunohisto-
chemistry. Kuniyasu et al (1998) and Suda et al (1999) demon-
strated that high expression of TS was observed in 42% and 46%
of cases, respectively. This may be explained by differences in the
antibodies used for TS immunostaining and in the stage distribu-
tion of the patients. In the study by Kuniyasu et al (1998), 28% of
patients had early gastric cancer, and only stage IIIB patients were
included in the study by Suda et al (1999). 
In the current study, high TS expression was associated with
poorly differentiated histology in tumour grade and mixed type in
Lauren’s classification. While the prognostic significance of
poorly differentiated histology in gastric cancer is controversial,
several studies have demonstrated that mixed type in Lauren’s
classification is associated with poor prognosis and other factors
suggesting aggressive biologic behavior such as lymph node
metastasis and advanced stage (Shiu et al, 1989; Kim et al, 1992;
Carneiro et al, 1995; Macdonald et al, 1995; Yu et al, 1995; Setälä
et al, 1996; Stelzner and Emmrich, 1997). Unlike the present
results, other studies with gastric cancer tissue have failed to
show any relationship between TS expression and tumour differ-
entiation or Lauren’s classification (Kuniyasu et al, 1998; Yeh et
al, 1998; Suda et al, 1999). Considering the fact that mixed-type
gastric cancer is associated with poor outcome of the patients,
high TS expression may suggest intrinsic aggressive tumour
behaviour. 
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Table 2 Disease-free and overall survival of the patients according to various characteristics 
Characteristics Patients (n) 4-year disease-free survival (%) P value 4-year overall survival (%) P value 
Primary tumour size 0.053 0.056 
≤ 5 cm 52 69.1 68.5 
> 5 cm 51 48.2 50.1 
Tumour location 0.022 0.029 
Lower 55 65.1 67.2 
Mid 33 54.6 52.4 
Upper 12 58.3 57.1 
Diffuse 3 0.0 0.0 
Tumour differentiation 0.667 0.717 
Well 13 69.2 68.4 
Moderate 31 58.1 58.1 
Poor or undifferentiated 38 57.3 59.2 
Signet-ring 17 52.9 52.3 
Mucinous 4 75.0 66.7 
Lauren’s classification 0.946 0.901 
Intestinal 57 59.7 58.3 
Diffuse 12 58.3 58.3 
Mixed 34 58.0 61.1 
Lymphatic invasion 0.430 0.307 
Yes 78 55.9 56.6 
No 25 68.0 68.0 
Depth of tumour invasion 0.309 0.452 
T2 42 69.1 67.6 
T3 58 53.0 54.8 
T4 3 33.3 33.3 
Lymph node involvement 0.524 0.407 
N0 18 77.8 77.8 
N1 41 60.8 59.8 
N2 28 49.5 53.1 
N3 16 50.0 48.2 
Stage 0.419 0.462 
IB 9 77.8 77.8 
II 28 71.4 70.6 
IIIA 31 57.9 57.1 
IIIB 17 40.3 47.1 
IV 18 50.0 48.1 
Treatment 0.866 0.781 
Chemotherapy + immunotherapy 59 59.3 59.2 
Chemotherapy 44 57.5 60.0 
Chemotherapy regimens 0.671 0.802 
FA ± immunotherapy 70 61.4 61.2 
FAMa 33 51.2 55.4 
aF, 5-FU; A, doxorubicin; M, mitomycin-C. High TS expression was associated with a high proportion of
male gender in the current study. It was an unexpected finding
considering the previous reports, and further studies would be
necessary to find a possible explanation for such a result (Kuniyasu
et al, 1998; Yeh et al, 1998; Suda et al, 1999). TS expression was
not associated with other characteristics of prognostic significance
such as primary tumour size, depth of tumour invasion, lymph
node metastasis and postoperative pathologic stage. Kuniyasu et al
(1998) demonstrated a significant correlation between high TS
expression and advanced stage. However, a significant proportion
of the patients in their study had early gastric cancer, which makes
comparison with our results difficult. 
In gastric cancer, TS expression predicted increased risk of
recurrence and poor survival in patients treated with adjuvant
chemotherapy after surgical resection in a few studies (Kuniyasu
et al, 1998; Suda et al, 1999). However, in the current study, there
were no significant differences in disease-free survival and overall
survival between the high-TS group and low-TS group. These
results might have relevance to our findings of the lack of associa-
tion between TS expression and important prognostic factors such
as pathologic stage. The discrepant findings between the current
study and the previous reports in terms of prognostic implications
of TS could be explained as follows. First, the TS expression in
primary tumours of gastric cancer patients may not reflect the
ability of the tumour to induce TS protein or undergo TS gene
amplification with exposure to chemotherapeutic agents (Johnston
et al, 1994; Pestalozzi et al, 1997). Secondly, all patients in this
study were treated with doxorubicin as well as 5-FU, while other
studies demonstrating increased risk of recurrence and poor
survival in gastric cancer patients with high TS expression used 5-
FU or tegafur-uracil with or without mitomycin-C (Kuniyasu et al,
1998; Suda et al, 1999). Therefore, doxorubicin might have played
a role in the failure of high TS expression to predict poor survival
of patients. Thirdly, it is also possible that adjuvant chemotherapy
did not affect survival regardless of TS expression, which may
explain the lack of difference in survival between high-TS and low-
TS groups in the current study. Alternatively, there is a possibility
that the gastric cancer patients with high TS expression might
experience a greater survival benefit from adjuvant chemotherapy
compared to patients with low TS expression, as shown in other
studies with rectal cancer and breast cancer (Johnston et al, 1994;
Pestalozzi et al, 1997). In the current study, there was no significant
difference in survival according to important prognostic variables
such as Lauren’s classification, lymph node metastasis and patho-
logic stage. These results suggest the possibility that the prognostic
significance of various prognostic factors including TS expression
may disappear with the use of adjuvant chemotherapy, bringing the
survival curves closer. However, a larger study including patients
treated with surgical resection alone would be essential to prove
the latter two speculations. 
In conclusion, high TS expression did not predict poor disease-
free and overall survival in patients with locally advanced gastric
cancer treated with 5-FU and doxorubicin-based chemotherapy
after curative resection, although it was associated with poorly
differentiated histology and mixed type of tumour in Lauren’s
classification. Further prospective study with a large number of
patients, including the evaluation of other biological markers asso-
ciated with the resistance to 5-FU and doxorubicin such as thymidine
kinase, P-glycoprotein, multidrug resistance-associated protein, and
topoisomerase II, would seem to be necessary. 
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